Jéssica Barreto Ribeiro Dos Santos1, Michael Ruberson Ribeiro da Silva2. 1. Health Technology Assessment and Economy Group, Center for Exact, Natural and Health Sciences, Federal University of Espírito Santo, Alto Universitário S/N, Guararema, Alegre, Espírito Santo, 29500-000, Brazil. 2. Health Technology Assessment and Economy Group, Center for Exact, Natural and Health Sciences, Federal University of Espírito Santo, Alto Universitário S/N, Guararema, Alegre, Espírito Santo, 29500-000, Brazil. mruberson@gmail.com.
Abstract
PURPOSE: The involvement of the orexin system in the physiopathology of insomnia has been rapidly increasing in understanding. In this sense, daridorexant was the third orexin receptor antagonist approved by the FDA in January 2022. This review aims to summarize the chemistry, pharmacodynamics, pharmacokinetics, efficacy, safety, and tolerability profile of daridorexant for the treatment of insomnia disorder. METHODS: We performed a review of daridorexant for the treatment of insomnia disorder. The search was carried out in Medline via PubMed, Embase, and clinical trials, up to March 2022. RESULTS: Daridorexant 25 and 50 mg had more significant improvement for the wake after sleep onset (WASO), latency to persistent sleep (LPS), and subjective total sleep time (sTST) than placebo. In addition, daridorexant 50 mg was better for Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) than placebo. The most common adverse events were nasopharyngitis and headache. CONCLUSION: Daridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare daridorexant with benzodiazepines, benzodiazepine receptor agonists, sedative antidepressants, and other orexin receptor antagonists are required.
PURPOSE: The involvement of the orexin system in the physiopathology of insomnia has been rapidly increasing in understanding. In this sense, daridorexant was the third orexin receptor antagonist approved by the FDA in January 2022. This review aims to summarize the chemistry, pharmacodynamics, pharmacokinetics, efficacy, safety, and tolerability profile of daridorexant for the treatment of insomnia disorder. METHODS: We performed a review of daridorexant for the treatment of insomnia disorder. The search was carried out in Medline via PubMed, Embase, and clinical trials, up to March 2022. RESULTS: Daridorexant 25 and 50 mg had more significant improvement for the wake after sleep onset (WASO), latency to persistent sleep (LPS), and subjective total sleep time (sTST) than placebo. In addition, daridorexant 50 mg was better for Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) than placebo. The most common adverse events were nasopharyngitis and headache. CONCLUSION: Daridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare daridorexant with benzodiazepines, benzodiazepine receptor agonists, sedative antidepressants, and other orexin receptor antagonists are required.
Authors: Maria Calem; Jatinder Bisla; Aysha Begum; Michael Dewey; Paul E Bebbington; Traolach Brugha; Claudia Cooper; Rachel Jenkins; James Lindesay; Sally McManus; Howard Meltzer; Nicola Spiers; Scott Weich; Robert Stewart Journal: Sleep Date: 2012-03-01 Impact factor: 5.849
Authors: W Joseph Herring; Kathryn M Connor; Neely Ivgy-May; Ellen Snyder; Ken Liu; Duane B Snavely; Andrew D Krystal; James K Walsh; Ruth M Benca; Russell Rosenberg; R Bart Sangal; Kerry Budd; Jill Hutzelmann; Heather Leibensperger; Samar Froman; Christopher Lines; Thomas Roth; David Michelson Journal: Biol Psychiatry Date: 2014-10-23 Impact factor: 13.382
Authors: Emmanuel Mignot; David Mayleben; Ingo Fietze; Damien Leger; Gary Zammit; Claudio L A Bassetti; Scott Pain; Dalma Seboek Kinter; Thomas Roth Journal: Lancet Neurol Date: 2022-02 Impact factor: 44.182
Authors: Russell Rosenberg; Patricia Murphy; Gary Zammit; David Mayleben; Dinesh Kumar; Shobha Dhadda; Gleb Filippov; Antonia LoPresti; Margaret Moline Journal: JAMA Netw Open Date: 2019-12-02